Immuneering Appoints Andrew Gengos CFO
Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026
The appointment of Andrew Gengos as CFO is likely to be viewed positively by the market for Immuneering, as his extensive experience in biotech finance and corporate development could enhance the company's strategic growth and investor relations. This move signals a strengthening of Immuneering's leadership as it advances its lead oncology candidate, atebimetinib, into a pivotal Phase 3 trial, potentially increasing investor confidence in its future prospects.
Immuneering Corporation, a late-stage clinical oncology company, announced the appointment of Andrew Gengos as its new Chief Financial Officer, effective July 16, 2026. Mr. Gengos brings over 25 years of leadership experience in the biotech sector, having previously served as CFO and Head of Corporate Development at Terns Pharmaceuticals, which was acquired by Merck & Co., Inc. His role at Immuneering will encompass financial strategy, capital allocation, investor relations, business development, and corporate development, particularly as the company progresses its lead oncology candidate, atebimetinib, into Phase 3 clinical trials for pancreatic cancer. This strategic hire is expected to bolster Immuneering's capabilities during a critical growth phase.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard